Corey E - Search Results

1

BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.

Varkaris A, Wang K, Nouri M, Kozlova N, Schmidt DR, Stavridi A, Arai S, Ambrosio N, Poluben L, Jimenez-Vacas JM, Westaby D, Carmichael J, Xie F, Figueiredo I, Buroni L, Neeb A, Gurel B, Chevalier N, Brown L, Voznesensky O, Chen SY, Russo JW, Yuan X, Juric D, Beltran H, De Bono JS, Vander Heiden MG, Einstein DJ, Muranen T, Corey E, Sharp A, Balk SP. Varkaris A, et al. Among authors: corey e. Nat Commun. 2025 May 28;16(1):4931. doi: 10.1038/s41467-025-60238-x. Nat Commun. 2025. PMID: 40436896 Free PMC article.

2

Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.

Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL. Corey E, et al. Clin Cancer Res. 2002 Apr;8(4):1003-7. Clin Cancer Res. 2002. PMID: 11948106

3

Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.

Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Corey E, et al. Prostate. 2002 Jun 1;52(1):20-33. doi: 10.1002/pros.10091. Prostate. 2002. PMID: 11992617

4

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Corey E, et al. Clin Cancer Res. 2003 Jan;9(1):295-306. Clin Cancer Res. 2003. PMID: 12538482

5

Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function.

Brubaker KD, Vessella RL, Brown LG, Corey E. Brubaker KD, et al. Among authors: corey e. Prostate. 2003 Jun 15;56(1):13-22. doi: 10.1002/pros.10233. Prostate. 2003. PMID: 12746842

6

Bone morphogenetic protein signaling in prostate cancer cell lines.

Brubaker KD, Corey E, Brown LG, Vessella RL. Brubaker KD, et al. Among authors: corey e. J Cell Biochem. 2004 Jan 1;91(1):151-60. doi: 10.1002/jcb.10679. J Cell Biochem. 2004. PMID: 14689587

7

Metastases of prostate cancer express estrogen receptor-beta.

Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Lai JS, et al. Among authors: corey e. Urology. 2004 Oct;64(4):814-20. doi: 10.1016/j.urology.2004.05.036. Urology. 2004. PMID: 15491740

8

Osteoprotegerin in prostate cancer bone metastasis.

Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL. Corey E, et al. Cancer Res. 2005 Mar 1;65(5):1710-8. doi: 10.1158/0008-5472.CAN-04-2033. Cancer Res. 2005. PMID: 15753366

9

Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.

Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Quinn JE, et al. Among authors: corey e. Prostate Cancer Prostatic Dis. 2005;8(3):253-9. doi: 10.1038/sj.pcan.4500815. Prostate Cancer Prostatic Dis. 2005. PMID: 15999121

10

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.

Brubaker KD, Brown LG, Vessella RL, Corey E. Brubaker KD, et al. Among authors: corey e. BMC Cancer. 2006 Jan 17;6:15. doi: 10.1186/1471-2407-6-15. BMC Cancer. 2006. PMID: 16417633 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

669 results

Search Page

Filters